Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and 31P-MRS in a longitudinal cohort study, we aimed to investigate the effects of the s...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sharmaine Thirunavukarasu, Nicholas Jex, Amrit Chowdhary, Imtiaz Ul Hassan, Sam Straw, Thomas P. Craven, Miroslawa Gorecka, David A. Broadbent, Peter Swoboda, Klaus K. Witte, Richard M. Cubbon, Hui Xue, Peter Kellman, John P. Greenwood, Sven Plein, Eylem Levelt
Format: Artigo
Jezik:engleski
Izdano: 2021
Online pristup:https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Internet

https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf

Slični predmeti